MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro

Renal fibrosis is a common pathological feature of various kidney diseases, leading to irreversible renal failure and end-stage renal disease. However, there are still no effective treatments to reverse renal fibrosis. This study aimed to explore the potential mechanism of a targeted drug for fibros...

Full description

Bibliographic Details
Main Authors:	Meiling Chen, Yihang Yu, Tao Mi, Qitong Guo, Bin Xiang, Xiaomao Tian, Liming Jin, Chunlan Long, Lianju Shen, Xing Liu, Jianbo Pan, Yuanyuan Zhang, Tao Xu, Deying Zhang, Guanghui Wei
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Cells
Subjects:	chronic kidney diseases renal fibrosis MK-2206 Akt/mTOR signaling pathway
Online Access:	https://www.mdpi.com/2073-4409/11/21/3505

Similar Items

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
by: Hai-Ling Gao, et al.
Published: (2023-07-01)

Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells
by: Sofia Appelberg, et al.
Published: (2020-01-01)

Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells
by: Baocheng Gong, et al.
Published: (2021-07-01)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
by: Anna Richter, et al.
Published: (2021-03-01)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
by: Elizabeth H. Stover, et al.
Published: (2022-04-01)

Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
by: Baocheng Gong, et al.
Published: (2022-08-01)

The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells
by: Yu-Liang Li, et al.
Published: (2019-11-01)

High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors
by: Daniel J. Smit, et al.
Published: (2020-09-01)

The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line
by: Saeid Taghiloo, et al.
Published: (2022-04-01)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
by: Grabinski Nicole, et al.
Published: (2012-11-01)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
by: Elizabeth K. Lee, et al.
Published: (2020-05-01)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01)

Expression of mTOR in normal and pathological conditions
by: A Marques-Ramos, et al.
Published: (2023-07-01)

CCNG2 Overexpression Mediated by AKT Inhibits Tumor Cell Proliferation in Human Astrocytoma Cells
by: Danfeng Zhang, et al.
Published: (2018-04-01)

AKT inhibition sensitizes acute leukemia cells to S63845-induced apoptosis
by: Yunjian Li, et al.
Published: (2023-12-01)

Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
by: Kyung Hwan Kim, et al.
Published: (2020-09-01)

Overview of Research into mTOR Inhibitors
by: Beibei Mao, et al.
Published: (2022-08-01)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
by: James T. Murray, et al.
Published: (2018-05-01)

Clinical Implications of mTOR Expression in Papillary Thyroid Cancer—A Systematic Review
by: Aleksandra Derwich, et al.
Published: (2023-03-01)

Medical Aspects of mTOR Inhibition in Kidney Transplantation
by: Elena Cuadrado-Payán, et al.
Published: (2022-07-01)

The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
by: Eleni A. Karatrasoglou, et al.
Published: (2023-09-01)

Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Regulates Neurite Outgrowth Through the Activation of Akt/mTOR and Erk/mTOR Signaling Pathways
by: Wen Wen, et al.
Published: (2020-09-01)

mTOR Pathways in Cancer and Autophagy
by: Mathieu Paquette, et al.
Published: (2018-01-01)

Modulation of the mTOR Pathway by Curcumin in the Heart of Septic Mice
by: Bruna A. C. Rattis, et al.
Published: (2022-10-01)

mTOR pathway somatic variants and the molecular pathogenesis of hemimegalencephaly
by: Camila A. B. Garcia, et al.
Published: (2020-03-01)

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy
by: Abdelhakim Bouyahya, et al.
Published: (2022-11-01)

mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership
by: Angel Cayo, et al.
Published: (2021-07-01)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
by: Letizia Todeschini, et al.
Published: (2023-06-01)

mTOR Signaling Pathway in Bone Diseases Associated with Hyperglycemia
by: Shuangcheng Wang, et al.
Published: (2023-05-01)

Orf virus induces complete autophagy to promote viral replication via inhibition of AKT/mTOR and activation of the ERK1/2/mTOR signalling pathway in OFTu cells
by: Lijun Lv, et al.
Published: (2023-03-01)

Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma
by: Luca Felkai, et al.
Published: (2020-07-01)

mTOR inhibition: a promise for a young heart.
by: Stêfany Bruno De Assis Cau, et al.
Published: (2012-02-01)

Advances in the regulatory mechanisms of mTOR in necroptosis
by: Yawen Xie, et al.
Published: (2023-12-01)

The mTOR Signalling Pathway in Human Cancer
by: Paula Soares, et al.
Published: (2012-02-01)

Dose-dependent Effects of mTOR Inhibition on Weight and Mitochondrial Disease in Mice
by: Simon C Johnson, et al.
Published: (2015-07-01)

Editorial: mTOR pathway malfunctions in neurodevelopmental disorders
by: Xinqi Fang, et al.
Published: (2023-01-01)

The Mitochondrial Deubiquitinase USP30 Regulates AKT/mTOR Signaling
by: Ruohan Zhang, et al.
Published: (2022-02-01)

Protective Effects of Fluvastatin on Reproductive Function in Obese Male Rats Induced by High-Fat Diet through Enhanced Signaling of mTOR
by: Xiangrong Cui, et al.
Published: (2017-02-01)

Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
by: Fen Zhang, et al.
Published: (2023-10-01)

Targeting the PI3K/Akt/mTOR Signaling Pathway: Applications of Nanotechnology
by: Forough Alemi Serej, et al.
Published: (2018-01-01)